Cardiol Therapeutics Files 6-K, Confirms 20-F Reporting
Ticker: CRDL · Form: 6-K · Filed: Feb 26, 2024 · CIK: 1702123
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, compliance
TL;DR
**Cardiol Therapeutics just filed a routine 6-K, confirming their foreign private issuer status and 20-F annual reporting.**
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K with the SEC on February 26, 2024, indicating it is a foreign private issuer. The filing confirms the company submits annual reports under Form 20-F and includes Exhibit 99.1, described as a "Material Change R." The company's business address is 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Why It Matters
This filing confirms Cardiol Therapeutics' regulatory compliance as a foreign private issuer, providing transparency to investors regarding its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain information indicating significant financial or operational risks.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — registrant
- February 2024 (date) — month of report
- 001-40712 (other) — Commission File Number
- 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5 (other) — principal executive offices address
- Form 20-F (other) — annual report form
- Exhibit 99.1 (other) — material change exhibit
FAQ
What type of report did Cardiol Therapeutics Inc. file?
Cardiol Therapeutics Inc. filed a Form 6-K, which is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934'.
When was this 6-K filing submitted?
The 6-K filing was submitted on February 26, 2024, for the month of February 2024.
Under which form does Cardiol Therapeutics Inc. file its annual reports?
Cardiol Therapeutics Inc. indicates that it files its annual reports under Form 20-F.
What is the Commission File Number for Cardiol Therapeutics Inc.?
The Commission File Number for Cardiol Therapeutics Inc. is 001-40712.
What exhibit was submitted with this 6-K filing?
Exhibit 99.1, described as 'Material Change R', was submitted with this 6-K filing.
Filing Stats: 207 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-02-26 10:06:30
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 14KB
- exhibit99-1xm001.jpg (GRAPHIC) — 8KB
- 0001062993-24-004351.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: February 26, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer